Literature DB >> 12395890

Azithromycin-induced intrahepatic cholestasis.

Sreekanth Chandrupatla1, Anthony J Demetris, Mordechai Rabinovitz.   

Abstract

Azithromycin (Zithromax), an erythromycin derivative that belongs to a subgroup of the macrolides known as azolides, has generally been considered to be a very safe medication. Hepatic side effects are uncommon but may include jaundice, fever, and right upper quadrant pain. Herein we describe a patient who developed azithromycin-induced cholestatic hepatitis that resolved upon discontinuation of the drug. Lack of other known causes for liver disease, the temporal relationship with this drug, and the typical changes of liver histology have established the diagnosis. Clinicians should be aware of this side effect of azithromycin, which is widely prescribed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12395890     DOI: 10.1023/a:1020170807742

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  9 in total

1.  Hypersensitivity syndrome associated with azithromycin.

Authors:  R I Cascaval; D J Lancaster
Journal:  Am J Med       Date:  2001-03       Impact factor: 4.965

2.  Azithromycin-induced intrahepatic cholestasis.

Authors:  G Longo; C Valenti; G Gandini; L Ferrara; M Bertesi; G Emilia
Journal:  Am J Med       Date:  1997-02       Impact factor: 4.965

Review 3.  Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients.

Authors:  N Principi; S Esposito
Journal:  Drug Saf       Date:  1999-01       Impact factor: 5.606

Review 4.  Hepatotoxicity of erythromycin.

Authors:  P Braun
Journal:  J Infect Dis       Date:  1969-03       Impact factor: 5.226

5.  Azithromycin for treatment of community acquired pneumonia caused by Legionella pneumophila: a retrospective study.

Authors:  I Kuzman; I Soldo; S Schönwald; J Culig
Journal:  Scand J Infect Dis       Date:  1995

Review 6.  Antibacterial-induced hepatotoxicity. Incidence, prevention and management.

Authors:  D K George; D H Crawford
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

7.  Fulminant hepatic failure associated with intravenous erythromycin lactobionate.

Authors:  C F Gholson; G H Warren
Journal:  Arch Intern Med       Date:  1990-01

8.  Erythromycin-associated cholestatic hepatitis.

Authors:  L E Derby; H Jick; D A Henry; A D Dean
Journal:  Med J Aust       Date:  1993-05-03       Impact factor: 7.738

9.  Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution.

Authors:  A E Girard; D Girard; A R English; T D Gootz; C R Cimochowski; J A Faiella; S L Haskell; J A Retsema
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

  9 in total
  7 in total

1.  Clinical and histologic features of azithromycin-induced liver injury.

Authors:  Melissa A Martinez; Raj Vuppalanchi; Robert J Fontana; Andrew Stolz; David E Kleiner; Paul H Hayashi; Jiezhun Gu; Jay H Hoofnagle; Naga Chalasani
Journal:  Clin Gastroenterol Hepatol       Date:  2014-08-09       Impact factor: 11.382

Review 2.  Hepatotoxicity of antibacterials: Pathomechanisms and clinical.

Authors:  J M Leitner; W Graninger; F Thalhammer
Journal:  Infection       Date:  2010-01-27       Impact factor: 3.553

Review 3.  Hepatic safety of antibiotics used in primary care.

Authors:  Raúl J Andrade; Paul M Tulkens
Journal:  J Antimicrob Chemother       Date:  2011-05-17       Impact factor: 5.790

4.  Azithromycin induced hepatocellular toxicity and hepatic encephalopathy in asymptomatic dilated cardiomyopathy.

Authors:  Bidyut Kumar Das
Journal:  Indian J Pharmacol       Date:  2011-11       Impact factor: 1.200

5.  A case of acute hepatitis with Mycoplasma pneumoniae infection and transient depression of multiple coagulation factors.

Authors:  Joo Hee Chang; Young Se Kwon; Bok Ki Kim; Byong Kwan Son; Jee Eun Lee; Dae Hyun Lim; Soon Ki Kim; Joon Mi Kim; Sung Kil Kang
Journal:  Yonsei Med J       Date:  2008-12-31       Impact factor: 2.759

6.  A case of prolonged cholestatic hepatitis induced by azithromycin in a young woman.

Authors:  Caterina Maggioli; Luca Santi; Giacomo Zaccherini; Vittoria Bevilacqua; Francesca Giunchi; Paolo Caraceni
Journal:  Case Reports Hepatol       Date:  2012-01-11

7.  Intrahepatic cholestasis of pregnancy or azithromycin-induced intrahepatic cholestasis: A case report.

Authors:  Baoshi Han; Yan Sheng; Li Wang; Hao Feng; Xianzeng Hou; Yan Li
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.